Document is current
Any future updates will be listed below
-
Authors
Schmidt, Ralf
Bajerski, Dion
Bicu, Alicia S.
Siefert, Victor
Eckl, Miriam
Willam, Marvin
Froelich, Matthias F.
Schoenberg, Stefan O.
Ehmann, Michael
Buergy, Daniel
Stieler, Florian
Fleckenstein, Jens
Giordano, Frank A.
Boda-Heggemann, Judit
Dreher, Constantin
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 5 December 2025
Accepted: 25 March 2026
First Online: 11 April 2026
Competing interests
: C.D. reports Varian research grant and travel expenses, AstraZeneca speaker fees and travel expenses, and DGVS speaker fees and travel expenses. D.B. reports NB Capital ApS (honoraria, consultation fees), PharmaMar GmbH (honoraria) and AstraZeneca GmbH (speaker fees and travel expenses). J.B-H. reports AstraZeneca speaker fees and consulting honoraria EbaMed SA. F.A.G. reports travel expenses, stocks and honoraria from TME Pharma AG; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; grants, research grants, travel expenses and honoraria from OncoMANGETx, Inc.; travel expenses and research grants from Varian Medical Systems, Inc.; travel expenses and/or honoraria from Bristol- Myers Squibb, Cureteq AG, Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems, and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG and patent EP4119191A1.
